胰高血糖素样肽 1 (GLP-1) 受体激动剂与 Control-IQ 技术配合使用对 2 型糖尿病的益处

{"title":"胰高血糖素样肽 1 (GLP-1) 受体激动剂与 Control-IQ 技术配合使用对 2 型糖尿病的益处","authors":"Roy W. Beck, Carol J Levy, Y. C. Kudva, Keta Pandit, Thomas Blevins, Dan Raghinaru, J. Pinsker","doi":"10.2337/cd23-0107","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":" 22","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes\",\"authors\":\"Roy W. Beck, Carol J Levy, Y. C. Kudva, Keta Pandit, Thomas Blevins, Dan Raghinaru, J. Pinsker\",\"doi\":\"10.2337/cd23-0107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":39894,\"journal\":{\"name\":\"Clinical Diabetes\",\"volume\":\" 22\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2337/cd23-0107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/cd23-0107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}